Evidence map›Paper›PMID 40754718›Full record

Trial reportThe Journal of antimicrobial chemotherapy2025

Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial.

Sean W X Ong, Ruxandra Pinto, Asgar Rishu, Steven Y C Tong, Robert A Fowler, Nick Daneman, BALANCE trial consortium

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sean W X OngInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.ORCID 0000-0002-8570-436X
Ruxandra PintoInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.ORCID 0000-0003-3712-4624
Asgar RishuSunnybrook Health Sciences Centre, Toronto, Canada.
Steven Y C TongDepartment of Infectious Diseases, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-1368-8356
Robert A FowlerInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
Nick DanemanInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
BALANCE trial consortium

Funding

Australian National Medical Research CouncilCIHRGovernment of Ontario, CanadaHealth Research Council of New ZealandLong-term Care Innovation FundOntario Ministry of HealthPhysicians Services Incorporated OntarioQEII-GSSTUniversity of Melbourne, AustraliaUniversity of Toronto, Canada
6 · The paper itself

Abstract

objectivesThere is a lack of data describing the longitudinal clinical trajectories of vital signs and laboratory tests in patients with bloodstream infection (BSI). The BALANCE trial, which randomly assigned patients with BSI to receive 7 or 14 days of antibiotic treatment, provided rich daily data to describe these trajectories.

methodsAs part of the BALANCE trial, we collected several daily parameters (temperature, heart rate, mean arterial pressure, systolic blood pressure, respiratory rate, WBC count, C-reactive protein, platelet count and SOFA score) until Day 14 of illness, discharge or death. In this post hoc descriptive sub-study, we described trajectories of these parameters, stratified by treatment group allocation and by the primary outcome of 90-day all-cause mortality.

resultsAmong 3608 patients included, median age was 70 years and 46.7% were female. At enrolment, 55.0% were admitted in the ICU and 21.2% required mechanical ventilation. Longitudinal trajectories of vital signs, laboratory tests and SOFA scores were almost identical comparing the two treatment groups, including from Day 7 after treatment divergence. These trajectories were markedly different when comparing survivors (3034 patients; 84.7%) and non-survivors (547 patients; 15.3%), with non-survivors demonstrating a slower recovery course throughout the 14-day period.

conclusionsAmong hospitalized patients with BSI, recovery trajectories were similar in patients assigned to 7- versus 14-day antibiotic treatment durations but were different comparing survivors versus non-survivors. These data could be used to inform daily clinical management, formulate predictive risk scores or clinical decision rules, and guide future research into individualized therapeutic strategies.

Indexed as

Anti-Bacterial AgentsBacteremiaSepsisAgedAged, 80 and overFemaleHumansMaleMiddle AgedTreatment OutcomeVital SignsAnti-Bacterial Agents

Identifiers

PMID40754718
PMCPMC12494135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.